stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Revenue
Lakefront Biotherapeutics - Sponsored ADR's revenue for fiscal 2025 was $1.3B, up 321.9% from $298.3M in fiscal 2024. Over the twelve months to 31 March 2026 it was $282.0M. Over the past ten years it has ranged from $67.3M (fiscal 2015) to $1.3B (fiscal 2025) — the current reading is the highest in ten years. Lakefront Biotherapeutics - Sponsored ADR ranks 58th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.3B | 321.88% |
| FY2024 | $298.3M | 14.96% |
| FY2023 | $259.5M | (51.26%) |
| FY2022 | $532.4M | (7.19%) |
| FY2021 | $573.6M | (5.30%) |
| FY2020 | $605.7M | (39.63%) |
| FY2019 | $1.0B | 167.31% |
| FY2018 | $375.4M | 113.00% |
| FY2017 | $176.2M | 5.04% |
| FY2016 | $167.8M | 149.42% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Mar 2026 | $7.6M | (90.40%) |
| Mar 2025 | $79.0M | 16.53% |
| Mar 2024 | $67.8M | (46.92%) |
| Sep 2023 | $127.7M | (21.66%) |
| 28 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| VCEL Vericel Corporation compare | $324.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $321.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $282.0M |
| SEPN Septerna, Inc. compare | $98.9M |
| PVLA Palvella Therapeutics, Inc. compare | $41.6M |
| ZYME Zymeworks Inc. compare | $37.1M |
| IMNM Immunome, Inc. compare | $12.6M |
| VERA Vera Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LKFT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement